阿托伐他汀對(duì)AECOPD患者血清GM-CSF及肺功能的影響
[Abstract]:Aim: to investigate the effects of Atto vastatin on serum granulocyte-giant cell colony-stimulating factor (GM-CSF) levels and pulmonary function in patients with acute exacerbation of chronic obstructive pulmonary disease (Acute exacerbation ofchronic obstructive pulmonary disease, AECOPD). Methods: 44 patients with AECOPD were randomly divided into control group (n = 20) and treatment group (n = 24). The control group was treated with AECOPD according to the routine treatment routine, and the treatment group was treated with 20 mg of Atto vastatin once a day on the basis of routine treatment. Lung function was measured on the first day of admission and 14 days after treatment. Serum GM-CSF was collected and serum GM-CSF content was measured by ELISA method. Finally, the data were analyzed statistically: the data were processed by SPSS19.0 software. The data were expressed as x 鹵s, the two groups were treated with independent sample t test, the relationship between two variables before and after treatment was matched t test, the serum GM-CSF and FEV1%pre levels were analyzed by linear correlation analysis, the test level was 偽 0.05. Results (1) after 14 days of treatment, FEV1%pre in the treatment group and control group was significantly higher than that before treatment (P0.01). The serum GM-CSF in the treatment group and control group was significantly lower than that in the control group after 14 days of treatment (P0.01). There was a negative correlation between serum GM-CSF and FEV1%pre in the AECOPD patients (P0.01). 4) there was no significant difference in serum GM-CSF level between the treatment group and the control group after 14 days of treatment (P0.05). Conclusion after treatment, the level of serum GM-CSF and pulmonary function were decreased and the improvement of pulmonary function might be related to the recovery of serum GM-CSF. Atto vastatin could not significantly reduce the level of serum GM-CSF and improve pulmonary function in patients with AECOPD in a short time. The clinical observation and study of stable COPD patients were needed in the future.
【學(xué)位授予單位】:青海大學(xué)
【學(xué)位級(jí)別】:碩士
【學(xué)位授予年份】:2013
【分類號(hào)】:R563
【參考文獻(xiàn)】
相關(guān)期刊論文 前9條
1 王月州;;COPD患者治療前后血清NO、NOS和GM-CSF檢測(cè)的臨床意義[J];放射免疫學(xué)雜志;2011年06期
2 王媛媛;李國(guó)平;;粒細(xì)胞-巨噬細(xì)胞集落刺激因子在COPD中的研究進(jìn)展[J];西南軍醫(yī);2012年01期
3 白春學(xué);COPD的炎癥和抗炎研究進(jìn)展[J];臨床肺科雜志;2005年05期
4 王永彬;王偉;;辛伐他汀對(duì)COPD患者細(xì)胞凋亡和炎癥因子的干預(yù)作用[J];山東大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2009年08期
5 陳旭東;王偉;王永彬;;辛伐他汀對(duì)COPD大鼠模型炎癥的干預(yù)作用[J];山東大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2010年04期
6 楊永華;陳炯;;粒細(xì)胞巨噬細(xì)胞集落刺激因子在創(chuàng)面愈合中的應(yīng)用進(jìn)展[J];實(shí)用醫(yī)學(xué)雜志;2008年19期
7 張平;李衛(wèi)東;;辛伐他汀對(duì)慢性阻塞性肺疾病大鼠腫瘤壞死因子-α表達(dá)的影響及機(jī)制[J];中國(guó)藥物與臨床;2010年04期
8 仝重芳;李衛(wèi)東;趙卉;岳翠萍;張敏艷;;辛伐他汀對(duì)慢性阻塞性肺疾病大鼠白細(xì)胞介素-6基質(zhì)金屬蛋白酶-9表達(dá)的影響[J];中國(guó)藥物與臨床;2011年03期
9 夏書月;康健;何巍;許曉陽;何曉琳;王實(shí);;辛伐他汀對(duì)COPD急性加重期患者誘導(dǎo)痰血管內(nèi)皮生長(zhǎng)因子水平和肺功能的影響[J];中國(guó)呼吸與危重監(jiān)護(hù)雜志;2010年03期
本文編號(hào):2142064
本文鏈接:http://sikaile.net/yixuelunwen/huxijib/2142064.html